Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866716 | 1.00 | MAPT (0.50) | MAPTRXFP1KMT2AHDAC3HDAC4 | |
| SCHEMBL17221909 | 1.00 | MAPT (0.50) | MAPTRXFP1KMT2AHDAC3HDAC4 | |
| SCHEMBL17417245 | 1.00 | MAPT (0.50) | MAPTRXFP1KMT2AHDAC3HDAC4 | |
| Acetic Acid SCHEMBL9526438 | 0.96 | RXFP1 (0.46) | MAPTRXFP1KMT2AHDAC3HDAC4 | |
| SCHEMBL2426303 | 0.88 | KEAP1 (0.44) | MAPTRXFP1HDAC3HDAC4HDAC1 | |
| SCHEMBL2530115 | 0.78 | AKR1B1 (0.41) | MAPTHDAC3HDAC4HDAC7HDAC8 | |
| SCHEMBL28062991 | 0.69 | KMT2A (0.57) | MAPTRXFP1KMT2AHDAC3HDAC4 | |
| SCHEMBL11817887 | 0.69 | MAPT (0.51) | MAPTRXFP1HDAC3HDAC4HDAC1 | |
| SCHEMBL2553009 | 0.68 | MAPT (1.00) | MAPTRXFP1HDAC3HDAC4HDAC1 | |
| SCHEMBL1008045 | 0.68 | MAPT (1.00) | MAPTRXFP1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1924548-B1 | ESTER PRODRUGS OF PROSTRATIN AND RELATED PHORBOL COMPOUNDS | SALVIA SCIENCES INC (US) | 2018-03-28 | — | — | EP | claimed |
| US-8431612-B2 | Ester prodrugs of prostratin and related phorbol compounds | SALVIA SCIENCES, INC. (US) | 2013-04-30 | — | — | US | claimed |
| US-20110251421-A1 | Ester Prodrugs of Prostratin and Related Phorbol Compounds | SALVIA SCIENCES, INC. (US) | 2011-10-13 | — | — | US | claimed |
| US-20250137015-A1 | YEAST PLATFORM FOR RENEWABLE INDUSTRIAL TERPENE PRODUCTION | Wang, Zhen (US) | 2025-05-01 | — | — | US | disclosed |
| CN-115403540-A | Comprehensive extraction and separation method of active ingredients of euphorbia lathyris seeds | 李玉山 | 2022-11-29 | — | — | CN | disclosed |
| CN-110540504-B | Preparation method of ingenane diterpene and application thereof in pharmacy | 复旦大学 | 2022-03-22 | — | — | CN | disclosed |
| CN-110540504-A | Preparation method of ingenane diterpene and application thereof in pharmacy | UNIV FUDAN | 2019-12-06 | — | — | CN | disclosed |
| EP-1924548-B1 | ESTER PRODRUGS OF PROSTRATIN AND RELATED PHORBOL COMPOUNDS | SALVIA SCIENCES INC (US) | 2018-03-28 | — | — | EP | disclosed |
| US-8431612-B2 | Ester prodrugs of prostratin and related phorbol compounds | SALVIA SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20110251421-A1 | Ester Prodrugs of Prostratin and Related Phorbol Compounds | SALVIA SCIENCES, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-8022103-B2 | Ester prodrugs of prostratin and related phorbol compounds | SALVIA SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090163587-A1 | ESTER PRODRUGS OF PROSTRATIN AND RELATED PHORBOL COMPOUNDS | SALVIA SCIENCES, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-1924548-A2 | ESTER PRODRUGS OF PROSTRATIN AND RELATED PHORBOL COMPOUNDS | Salvia Sciences, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007009055-A2 | ESTER PRODRUGS OF PROSTRATIN AND RELATED PHORBOL COMPOUNDS | SALVIA SCIENCES, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251421-A1 | Ester Prodrugs of Prostratin and Related Phorbol Compounds | PMAIP1, PTGIR, PTGDR | MAPT 2786/4885RXFP1 1060/4885KMT2A 3157/4885 |
| US-20090163587-A1 | ESTER PRODRUGS OF PROSTRATIN AND RELATED PHORBOL COMPOUNDS | PMAIP1, PTGIR, PTGDR | MAPT 3491/4885RXFP1 378/4885KMT2A 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.